An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy. Observations of process time included task time and active healthcare professional (HCP) time for pre-defined tasks. Patient time measurements included entering/exiting the DOU, treatment room, and treatment chair or examination table. RESULTS: A total of 189 patients were enrolled (82 received zoledronic acid and 107 received denosumab) and 238 observations were recorded (104 for zoledronic acid and 134 for denosumab). Mean total task time was reduced by 81% when denosumab was used versus zoledronic acid (8.4 versus 44.2 min; p < 0.0001; pooled analysis across all countries). Pooled estimates for active HCP time were 12.2 min for zoledronic acid and 6.9 min for denosumab (44% reduction; p < 0.0001). CONCLUSIONS: In the countries studied, using denosumab compared with zoledronic acid reduced total task time and active HCP time. Thus, HCPs have more time to dedicate to other patients or care activities. An ability to increase the volume of appointments within DOUs could reduce waiting lists in sites operating at full capacity and increase overall productivity and efficiency in hospital processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three publications reported directly measured time assessments for various oncology therapies; all of these publications demonstrated reduced administration time for therapies administered by the SC route versus the IV route [117–119].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“More than 70% of patients with advanced breast cancer [1], up to 90% of patients with advanced prostate cancer [2, 3] and 60% of patients with advanced lung cancer have radiologic evidence of bone Electronic supplementary material The online version of this article (doi:10.”
BackgroundClinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230 · cited 1×
“In a patient preference study conducted in individuals with breast cancer, strong patient preference was reported for SC versus IV administration of trastuzumab [25, 26].”
BackgroundImpact of skeletal complications on patients’ quality of life, mobility, and functional independence
Costa, L., Badia, X., Chow, E., Lipton, A., & Wardley, A. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0418-0 · Cited by 206
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177 · cited 1×
“In a patient preference study conducted in individuals with breast cancer, strong patient preference was reported for SC versus IV administration of trastuzumab [25, 26].”
BackgroundVogler, S., Vitry, A., & Babar, Z.-U.-D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00449-0 · Cited by 175
von Moos, R., Body, J.-J., Egerdie, B., Stopeck, A., Brown, J. E., Fallowfield, L. J., Patrick, D. L., Cleeland, C. S., Damyanov, D., Palazzo, F. G., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2908-1 · Cited by 114
Self-citationDe Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157957 · Cited by 108 · cited 1×
“As such, based on a similar published multi-site study [29], a site effect (i.”
BackgroundSelf-citationImproving Wait Time for Chemotherapy in an Outpatient Clinic at a Comprehensive Cancer Center
Kallen, M. A., Terrell, J. A., Lewis-Patterson, P. A., & Hwang, J. P. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000281 · Cited by 98
von Moos, R., Body, J.-J., Egerdie, B., Stopeck, A., Brown, J. E., Damyanov, D., Fallowfield, L. J., Marx, G., Cleeland, C. S., Patrick, D. L., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1932-2 · Cited by 95 · cited 1×
“tient HRQoL and strong opioid use were less common with denosumab than with zoledronic acid treatment [28].”
BackgroundSelf-citationBurden of skeletal-related events in prostate cancer: unmet need in pain improvement
Broder, M. S., Gutierrez, B., Cherepanov, D., & Linhares, Y. P. L. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2437-3 · Cited by 65
Hoefeler, H., Duran, I., Hechmati, G., Garzon Rodriguez, C., Lüftner, D., Ashcroft, J., Bahl, A., Atchison, C., Wei, R., Thomas, E., et al. (2014) · Journal of Bone Oncology · doi:10.1016/j.jbo.2014.04.001 · Cited by 50 · cited 1×
“Thus, SREs are associated with substantial healthcare resource utilization consumption, placing an additional burden on healthcare systems [9, 10].”
BackgroundSelf-citationThe multidisciplinary approach to bone metastases.
Blum, R. H., Novetsky, D., Shasha, D., & Fleishman, S. B. (2003) · PubMed · Cited by 39
Matza, L., Cong, Chung, Stopeck, A., Tonkin, K., Brown, Braun, Brunt, V., & McDaniel, K. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s44947 · Cited by 38
Body, J., Pereira, J., Sleeboom, H. P., Maniadakis, N., Terpos, E., Acklin, Y. P., Fínek, J., Gunther, O., Hechmati, G., Mossman, T., et al. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0716-7 · Cited by 34 · cited 2×
“5 stays and an increase in the total duration of inpatient stays of 6–37 days per event [9].”
BackgroundSelf-citationPrice, value, and the cost of cancer drugs
Fojo, T., & Lo, A. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00564-1 · Cited by 24
Oglesby, A. K., Sherif, B. N., Odom, D. M., Leahy, M. G., & Qian, Y. (2009) · Community Oncology · doi:10.1016/s1548-5315(11)70357-6 · Cited by 18 · cited 3×
“4 min [20] was similar to the mean total time reported in our study (49 min for Belgium, 52 min for Germany and 31 min for Italy).”
BackgroundMethodResultInfluentialLöthgren, M., Ribnicsek, E., Schmidt, L., Habacher, W., Lundkvist, J., Pfeil, A. M., Biteeva, I., Vrouchou, P., & Bracco, A. (2013) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2012-000235 · Cited by 18
Barrett-Lee, P. J., Bloomfield, D., Dougherty, L., Harries, M., Laing, R. W., Patel, H., & Walker, M. D. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210543 · Cited by 17
Richhariya, A., Yi, Q., Zhao, Y., & Chung, K. (2012) · Cancer Management and Research · doi:10.2147/cmar.s27693 · Cited by 11
Cited by
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
von Moos, R., Costa, L., González‐Suárez, E., Terpos, E., Niepel, D., & Body, J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.003 · Cited by 152
“Unlike many bisphosphonates, which are administered intravenously, denosumab is given subcutaneously as a single 120-mg injection every 4 weeks, improving the convenience and acceptability of treatment for patients [49,53,100], as well as the time required from healthcare professionals to deliver the medication [101].”
BackgroundSelf-citationMcCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Yayan, J. (2020) · Cancer Control · doi:10.1177/1073274820934822 · Cited by 29
“Background Denosumab was first introduced in the year 2010 for the treatment of osteoporosis and now used at a high dosage to prevent skeletal-related complications in adults with solid bone metastases [1].”
BackgroundRog, D. J., Brownlee, W. J., Carod-Artal, F. J., Kalra, S., Barker, N., Lowndes, C., Pendlebury, J., Leclerc, S., Amin, A., Ashton, L., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105380 · Cited by 17
Noguchi, T., Sakamoto, A., Murotani, Y., Murata, K., Hirata, M., Yamada, Y., Toguchida, J., & Matsuda, S. (2023) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554231163638 · Cited by 11
Metadata
- Authors
- Body, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., Adamo, V., & Hechmati, G.
- Affiliations
- Université Libre de Bruxelles (BE)
- Amgen (Switzerland) (CH)
- University Hospital Carl Gustav Carus (DE)
- Jessa Hospital (BE)
- Antwerp University Hospital (BE)
- Policlinico San Matteo Fondazione (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Messina (IT)
- Corresponding author
- Body, Jean-Jacques
- ORCID
- Venue
- Supportive Care in Cancer
- Published
- 2017-04-21
- Volume
- 25
- Issue
- 9
- Pages
- 2823-2832
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- PMC
- PMC5527062
- OpenAlex
- W2606662033
- Cited by
- 11
- References
- 24
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2020: 2 · 2019: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Supportive Care in Cancer (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
- Funders
- Amgen (Europe) GmbH
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- denosumab, zoledronic acid, bone metastasis, subcutaneous injection, intravenous infusion, skeletal-related events, waiting lists
- MeSH terms
- Denosumab, Zoledronic Acid, Bone Neoplasms, Diphosphonates, Europe, Female, Humans, Imidazoles, Infusions, Intravenous, Injections, Subcutaneous, Male, Time and Motion Studies, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.